News about Global Pharma

Zydus Signs Licensing and Supply Agreement with Viwit Pharmaceuticals

As per the terms of the agreement, Viwit will be responsible for ANDA submission, manufacturing and supplying the generic versions of GADAVISTTM and DOTAREM, following the receipt of requisite regulatory approval.

Global Pharma | 16/09/2024 | By Aishwarya |  670

Refeyn Establishes New Mass Photometry Scientific Advisory Board

The new Scientific Advisory Board will convene regularly to explore and evaluate the transformative potential of mass photometry in critical customer workflows.

Global Pharma | 16/09/2024 | By Aishwarya |  671

Arrowhead Pharmaceuticals Secures FDA Breakthrough Therapy Designation for Plozasiran

Arrowhead intends to submit a New Drug Application to the FDA by year-end 2024 and plans to seek regulatory approval with additional global regulatory authorities thereafter.

Global Pharma | 13/09/2024 | By Aishwarya |  524

Halozyme Announces FDA Approval of Roche's Tecentriq Hybreza with ENHANZE

Tecentriq Hybreza can be injected subcutaneously in approximately 7 minutes compared to 30-60 minutes for standard intravenous (IV) infusion of Tecentriq (atezolizumab).

Global Pharma | 13/09/2024 | By Aishwarya |  527

Sunsure Energy to Energise Lupin's Tarapur Facility with 21 MW Solar Power

Through this agreement, Sunsure will supply solar power to Lupin’s Tarapur facility in India, sourced from its 100 MW (150 MWp) solar plant in Solapur.

Global Pharma | 13/09/2024 | By Aishwarya |  778

Varda Works with SSPC to Study Microgravity Crystallization

Varda and SSPC researchers based at the University of Limerick and the Mathematics Applications Consortium for Science and Industry (MACSI), Ireland, are collaborating on research that focuses on developing mathematical models for better understanding of how gravity influences crystallization and the resulting polymorphic outcomes.

Global Pharma | 12/09/2024 | By Aishwarya |  580

Johnson & Johnson Gets US FDA Approval for TREMFYA

TREMFYA is the first and only approved fully human, dual-acting monoclonal antibody that blocks IL-23 while also binding to CD64, a receptor on cells that produce IL-23.

Global Pharma | 12/09/2024 | By Aishwarya |  446

GenNext and Agilent to Boost High-Value Decision Making in Biopharmaceutical Research

The integration of GenNext's AutoFox Protein Footprinting System with Agilent's 6560 Ion Mobility Quadrupole Time-of-Flight (IM-QTOF) LC/MS System presents an unparalleled approach to detailed protein structure analysis and biomolecular interaction studies.

Global Pharma | 12/09/2024 | By Aishwarya |  523

Synaptogenix Raises USD 5 Million in Financing

Synaptogenix, Inc. has secured USD 5 million in financing through a combination of a registered public offering and a private placement.

Global Pharma | 12/09/2024 | By Aishwarya |  397

Roche Inaugurates Pharma Research and Development Center in Basel

Roche has launched its new Pharma Research and Early Development (pRED) Center at its global headquarters in Basel, Switzerland.

Global Pharma | 11/09/2024 | By Aishwarya |  963